Lisata Therapeutics, Inc. Common Stock
LSTAStock
$3.50+38.89%52W
Market Cap$32.78M
P/E—
Div yield—
Beta0.82
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)68.27%
Price vs S&P 500 (4W)6.85%
VGM Score38.67
Market Capitalization$32.78M
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.11
4.11
4.11
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LSTALisata Therapeutics, Inc. Common Stock | C | F | B | $3.50 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Lisata Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for solid tumors. Its lead candidate, certepetide, is designed to activate a proprietary uptake pathway that enhances the ability of co-administered anti-cancer drugs to penetrate and target solid tumors more effectively.